Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

September 14, 2019

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Prithviraj Bose, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses differences in the safety profiles of ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of myelofibrosis.

Bose believes ruxolitinib and fedratinib are similar in terms of efficacy and toxicity. Looking at ruxolitinib in the COMFORT trial and fedratinib in the JAKARTA trial, the rate of spleen volume reduction, total symptom score reduction and the incidence of the main adverse events, including anemia, and thrombocytopenia, are comparable, according to Bose.